Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- LDP, JPMA Exchange Opinions on How to Promote Clinical Trials in Japan
May 17, 2010
- Korosho, METI Set Up Joint Task Force to Promote New Growth Strategy
May 17, 2010
- Collategene Achieves Primary Endpoint in PIII Trial: AnGes MG
May 17, 2010
- PMDA Should Continue, Even Expand Its Activities: Screening by GRU
May 17, 2010
- Asahi Kasei's AT-877 Fails to Meet Primary Endpoint in PIII
May 17, 2010
- PMDA to Relax Working Regulations for Former Company Employees
May 17, 2010
- Hisamitsu's HKT-500 Fails to Meet Primary Endpoint in PIII
May 17, 2010
- Five NIBIO Projects Screened by GRU
May 17, 2010
- NIBIO Identifies Protein Related to Colon, Esophageal Cancer
May 17, 2010
- Takeda Obtains Approval for 5 Products, Including 1st In-house Product in 11 Years
May 3, 2010
- 6 Drugs, Including Orencia, Recommended for Approval
May 3, 2010
- Approval for Greater Strength Recommended for Pasil/Pazucross
May 3, 2010
- ASKA Aims at Sales of ¥50 Bil. in FY2012
May 3, 2010
- PMDA Must Accelerate Hiring of Reviewers: Mr Osa
May 3, 2010
- Shionogi, Eli Lilly Japan to Comarket Cymbalta
May 3, 2010
- PMDA, NIBIO to Be Targeted in 2nd Round of Screening
May 3, 2010
- Novartis Confident of Being Able to Differentiate Equa from Other DPP-4 Inhibitors
May 3, 2010
- PMDA's Reform Proposal Found Insufficient by Majority of Screeners: Internal Screening
May 3, 2010
- NEW PRODUCT
May 3, 2010
- MTPC Voluntarily Refrains from Promoting 7 Products Exempted from Sanction
May 3, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…